A 3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: In vivo studies and molecular mechanism of action

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Cohen, Shira ^a   Barer, Faina ^a   Bar Yehuda, Sara ^a   Ijzerman, Adriaan P ^b   Jacobson, Kenneth A ^c   Fishman, Pnina ^a  

^a Can Fite BioPharma Ltd   (Israel)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA ACTIN; CONCANAVALIN A; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; LUF 6000; PHOSPHATIDYLINOSITOL 3 KINASE; STAT1 PROTEIN; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; ANTIINFLAMMATORY AGENT; IMIDAZOLE DERIVATIVE; N-(3,4-DICHLOROPHENYL)-2-CYCLOHEXYL-1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINE;

ADJUVANT ARTHRITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOWN REGULATION; EXPERIMENTAL HEPATITIS; FEMALE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; OSTEOARTHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; RAT; RECEPTOR BINDING; TREATMENT DURATION; TUMOR LOCALIZATION; ANIMAL; ARTHRITIS, EXPERIMENTAL; C57BL MOUSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; INSTITUTE FOR CANCER RESEARCH MOUSE; LEWIS RAT; METABOLISM; ORAL DRUG ADMINISTRATION; SIGNAL TRANSDUCTION; WISTAR RAT;

ADENOSINE A3 RECEPTOR AGONISTS; ADMINISTRATION, ORAL; ALLOSTERIC REGULATION; AMINOQUINOLINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DRUG-INDUCED LIVER INJURY; FEMALE; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NF-KAPPA B; OSTEOARTHRITIS; RATS; RATS, INBRED LEW; RATS, WISTAR; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION;

EID: 84908338232     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/708746     Document Type: Article

References (32)

1. 3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. European Journal of Pharmacology 2003 466 3 323 329 10.1016/S0014-2999(03)01570-X 2-s2.0-0037453358
2. Fishman P., Bar-Yehuda S., Madi L., Rath-Wolfson L., Ochaion A., Cohen S., Baharav E., The PI3K-NF- B signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Research and Therapy 2006 8 1, article R33 10.1186/ar1887 2-s2.0-70449564383
3. Szabó C., Scott G. S., Virág L., Egnaczyk G., Salzman A. L., Shanley T. P., Haskó G., Suppression of macrophage inflammatory protein (MIP)-1 production and collagen-induced arthritis by adenosine receptor agonists. British Journal of Pharmacology 1998 125 2 379 387 10.1038/sj.bjp.0702040 2-s2.0-0031691973
4. 3 adenosine receptor expression. Arthritis Research and Therapy 2006 8 6, article R169 10.1186/ar2078 2-s2.0-34748913494
5. Bar-Yehuda S., Rath-Wolfson L., del Valle L., Ochaion A., Cohen S., Patoka R., Zozulya G., Barer F., Atar E., Piña-Oviedo S., Perez-Liz G., Castel D., Fishman P., Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. Arthritis and Rheumatism 2009 60 10 3061 3071 10.1002/art.24817 2-s2.0-70349778666
6. 3 adenosine receptor agonist CF101. International Journal of Molecular Medicine 2011 28 5 727 731 10.3892/ijmm.2011.753 2-s2.0-80053107312
7. 3 adenosine receptor as a target for cancer therapy. Anti-Cancer Drugs 2002 13 5 437 443 10.1097/00001813-200206000-00001 2-s2.0-0035987056
8. 3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF- B signaling. Immunobiology 2011 216 9 997 1003 10.1016/j.imbio.2011.03.008 2-s2.0-79960848582
9. 3 adenosine receptor agonists in murine autoimmune arthritis models. Journal of Rheumatology 2005 32 3 469 476 2-s2.0-15044343787
10. Haskó G., Szabó C., Németh Z. H., Kvetan V., Pastores S. M., Vizi E. S., Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. Journal of Immunology 1996 157 10 4634 4640 2-s2.0-0030588630
11. 3 receptors decreases interleukin-12 and interferon- γ production and prevents lethality in endotoxemic mice. European Journal of Pharmacology 1998 358 3 261 268 10.1016/S0014-2999(98)00619-0 2-s2.0-0032500375
12. 3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opinion on Investigational Drugs 2007 16 10 1601 1613 10.1517/13543784.16.10.1601 2-s2.0-35248857500
13. 3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Research and Therapy 2011 13 6, article R197 10.1186/ar3527 2-s2.0-82655177570
14. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clinical Cancer Research 2004 10 17 5895 5901 10.1158/1078-0432.CCR-1134-03 2-s2.0-4444247043
15. 3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cellular Immunology 2009 258 2 115 122 10.1016/j.cellimm.2009.03.020 2-s2.0-67649385777
16. 3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF- B signal transduction pathways. International Journal of Oncology 2008 33 2 287 295 10.3892/ijo-00000008 2-s2.0-48749128664
17. 3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. Journal of Rheumatology 2008 35 1 41 48 2-s2.0-38149051473
18. Avni I., Garzozi H. J., Barequet I. S., Segev F., Varssano D., Sartani G., Chetrit N., Bakshi E., Zadok D., Tomkins O., Litvin G., Jacobson K. A., Fishman S., Harpaz Z., Farbstein M., Yehuda S. B., Silverman M. H., Kerns W. D., Bristol D. R., Cohn I., Fishman P., Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology 2010 117 7 1287 1293 10.1016/j.ophtha.2009.11.029 2-s2.0-77954348601
19. David M., Akerman L., Ziv M., Kadurina M., Gospodinov D., Pavlotsky F., Yankova R., Kouzeva V., Ramon M., Silverman M. H., Fishman P., Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. Journal of the European Academy of Dermatology and Venereology 2012 26 3 361 367 10.1111/j.1468-3083.2011.04078.x 2-s2.0-84857366473
20. Birdsall N. J. M., Cohen F., Lazareno S., Matsui H., Allosteric regulation of G-protein-linked receptors. Biochemical Society Transactions 1995 23 1 108 111 2-s2.0-0028960231
21. 3 adenosine receptor. Journal of Medicinal Chemistry 2006 49 11 3354 3361 10.1021/jm060086s 2-s2.0-33744807197
22. 3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacology 2008 8, article 20 10.1186/1471-2210-8-20 2-s2.0-58549095278
23. 3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor- B in mediating receptor level. Journal of Rheumatology 2007 34 1 20 26 2-s2.0-33846246044
24. 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF- B signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochemical Pharmacology 2008 76 4 482 494 10.1016/j.bcp.2008.05.032 2-s2.0-48349143486
25. 3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. Journal of Cellular Physiology 2011 226 9 2438 2447 10.1002/jcp.22593 2-s2.0-79958698872
26. Lim H., Kim H. P., Matrix metalloproteinase-13 expression in IL-1 β -treated chondrocytes by activation of the p38 MAPK/c-Fos/AP-1 and JAK/STAT pathways. Archives of Pharmacal Research 2011 34 1 109 117 10.1007/s12272-011-0113-4 2-s2.0-79955066683
27. 3 adenosine receptor. Journal of Cellular Physiology 2001 186 1 19 23
28. 3 adenosine receptor induce G-CSF production via NF- B activation: a new class of myeloprotective agents. Experimental Hematology 2002 30 12 1390 1398 10.1016/S0301-472X(02)00962-1 2-s2.0-18744393077
29. 3 adenosine receptors. Journal of Cellular Physiology 2000 183 3 393 398 10.1002/(SICI)1097-4652(200006)183:3LTHEXA393::AID-JCP12>3.0.CO;2-G
30. Sandberg G., Fredholm B. B., Regulation of thymocyte proliferation: effects of L-alanine, adenosine and cyclic AMP in vitro. Thymus 1981 3 2 63 75 2-s2.0-0019469071
31. Pospíšil M., Hofer M., Znojil V., Netíková J., Vácha J., Holá J., Vacek A., Granulocyte colony-stimulating factor and drugs elevating extracellular adenosine synergize to enhance haematopoietic reconstitution in irradiated mice. European Journal of Haematology 1998 60 3 172 180 2-s2.0-0031894651
32. Pospíšil M., Hofer M., Znojil V., Vácha J., Netíková J., Holá J., Synergistic effect of granulocyte colony-stimulating factor and drugs elevating extracellular adenosine on neutrophil production in mice. Blood 1995 86 10 3692 3697 2-s2.0-0028875247